Investigators retrospectively assessed whether previous TKI therapy may affect response and survival outcomes in patients with relapsed or refractory acute myeloid leukemia.
Study results suggest that flotetuzumab demonstrates antileukemic activity in patients with primary induction failure and early-relapse acute myeloid leukemia.
A phase 3 trial showed a trend toward improved PFS with ixazomib plus lenalidomide and dexamethasone.
The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
The bispecific CAR-T therapy targets CD20 and CD19.
Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.
A fully human BCMA-directed CAR-T product showed clinical activity in patients with relapsed/refractory multiple myeloma.
A CAR-T therapy for myeloma that is manufactured using a unique process showed clinical activity and appeared safe, even in the outpatient setting.
Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.